ArticleMolecular psychiatry2021
Dopamine dysregulation in psychotic relapse after antipsychotic discontinuation: an [
Article in Molecular psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- EANM perspective on clinical PET and SPECT imaging in schizophrenia-spectrum disorders: a systematic review of longitudinal studies.European journal of nuclear medicine and molecular imaging · 2025Pooled it
- Psychotic relapse prediction via biomarker monitoring: a systematic review.Frontiers in psychiatry · 2024Pooled it
- Effect of add-on alpha lipoic acid on psychopathology in patients with treatment-resistant schizophrenia: a pilot randomized double-blind placebo-controlled trial.Psychopharmacology · 2022Trial
- What happens after tapering off antipsychotics? Clinical trajectories of 267 first-episode patients who discontinued antipsychotic medication.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026Article
- Dopamine synthesis capacity in patients with remitted psychosis: correlates and one year outcome on relapse.European archives of psychiatry and clinical neuroscience · 2026Article
- A Scoping Review of Methods, Guidelines, and Protocols Used for Dose Reduction or Discontinuation of Antipsychotic Medication in People Affected by Psychotic Disorders.Schizophrenia bulletin · 2026Article
- Dopamine DPsychological medicine · 2025Article
- Continuous Dopamine DThe American journal of psychiatry · 2025Article
- Amphetamine-Induced Dopamine Release Predicts 1-Year Outcome in First-Episode Psychosis: A Naturalistic Observation.Schizophrenia bulletin · 2024Observational
- A whole-brain neuromark resting-state fMRI analysis of first-episode and early psychosis: Evidence of aberrant cortical-subcortical-cerebellar functional circuitry.NeuroImage. Clinical · 2024Article
- Aberrant intra- and internetwork functional connectivity patterns of the anterior and posterior hippocampal networks in schizophrenia.CNS neuroscience & therapeutics · 2023Article
- The pharmacological treatment of schizophrenia: How far have we come?PCN reports : psychiatry and clinical neurosciences · 2022Review
- Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data.Schizophrenia bulletin · 2022Article
- A multimodal study of a first episode psychosis cohort: potential markers of antipsychotic treatment resistance.Molecular psychiatry · 2022Article
- Increased brain gyrification and subsequent relapse in patients with first-episode schizophrenia.Frontiers in psychiatry · 2022Article
- Magnetic resonance imaging of the dopamine system in schizophrenia - A scoping review.Frontiers in psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although antipsychotic drugs are effective for relieving the psychotic symptoms of first-episode psychosis (FEP), psychotic relapse is common during the course of the illness. While some FEPs remain remitted even without medication, antipsychotic discontinuation is regarded as the most common risk factor for the relapse. Considering the actions of antipsychotic drugs on presynaptic and postsynaptic dopamine dysregulation, this study evaluated possible mechanisms underlying relapse after antipsychotic discontinuation. Twenty five FEPs who were clinically stable and 14 matched healthy controls were enrolled. Striatal dopamine activity was assessed as K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.